Collectively, autoimmune diseases constitute a major, unmet, clinical challenge. Although no single autoimmune disorder is highly prevalent, there are over 80 of them, and 20% of the population is affected; approximately 75% of patients are women. Because these diseases are generally incurable and difficult to manage, there is a pressing need for novel approaches to their treatment. For reasons detailed below, we have proposed that gene therapy merits investigation in this regard.

**Why genes?**

Traditional pharmacological approaches to treatment entail the synthesis of small, diffusible compounds given orally or by injection. These approaches have yet to provide ideal agents for use in autoimmune diseases. Recent research, however, has identified a number of proteins with the potential to improve treatment, but these are difficult to administer long term. Gene transfer provides the opportunity to deliver protein products, as well as therapeutic species of nucleic acids, such as antisense RNA, much more efficiently than traditional methods of drug therapy. Furthermore sustained, in situ production of the gene products would eliminate the need for frequent re-administration. In addition, gene delivery and subsequent expression has the potential to be highly localised, if needed. Indeed, gene therapy’s greatest strength may be its ability to produce high, sustained concentrations of therapeutic macromolecules within a defined anatomical location. In the case of RA, for example, anti-arthritis proteins are already being delivered systemically to patients by subcutaneous or intravenous injection. There is, however, no practical method for transferring these molecules selectively to joints in a sustained fashion.

**Gene therapy**

In its broadest sense, gene therapy is the transfer to patients of a gene, or genes, for therapeutic purposes. With some exceptions, such as skeletal muscle and skin, naked DNA is not efficiently taken up and expressed by mammalian cells. For this reason it is necessary to use vectors as agents of gene transfer and gene expression. Most vectors presently in use for gene therapy are based upon viruses; retrovirus, adenovirus, adeno-associated virus and herpes simplex virus are most frequently used for this purpose. The wild type viruses have been genetically manipulated to render them incapable of replicating or otherwise causing disorders, while retaining their infectivity. Individual viral vectors have their idiosyncratic advantages and disadvantages. As a group they are difficult and expensive to produce in large amounts, and there are lingering concerns about safety. Non-viral vectors, such as liposomes, overcome some of these issues, but remain much less efficient than vectors based on viruses. Of particular concern to chronic conditions, such as autoimmune diseases, is the need for vectors that either give long term gene expression or lend themselves to frequent re-administration. Integrating viruses, such as retrovirus and adeno-associated virus, become established within the chromosomes of the host cells and provide the best prospects for long term gene expression. For non-integrating vectors such as adenovirus, which are only transiently expressed, it is probable that repeated administration will require the vectors to be rendered non-immunogenic. For most applications, therapeutic genes encoding native, human proteins are likely to be used in which case the gene products should not be antigenic. Viral coat proteins, however, are highly antigenic; thus repeated administration of a viral vector will require the patient to be immunosuppressed or tolerant to the virus. Making patients tolerant to potentially pathogenic agents may be unwise but immunosuppressive drugs, already used as part of the standard treatment of autoimmune diseases, could be helpful. Many non-viral vector systems have the advantage of being non-antigenic.

Regardless of the vector system that is used, gene transfer to the target tissues may be accomplished by in vivo or ex vivo strategies. In the former, vectors are injected directly into the body. In the latter, cells are removed, genetically altered outside the body, and then returned to the individual. Ex vivo delivery is clearly more tedious, expensive, and cumbersome, but it permits selection and scrutiny of the genetically altered cells before re-implantation. For many types of cells that divide readily in vitro, but rarely in vivo, it permits use of Moloney-based retroviral vectors, able only to infect replicating cells. For these sorts of reasons, ex vivo gene delivery has made the greatest initial progress and most human gene therapy trials use this strategy. Nevertheless, the development of improved vectors for in vivo gene delivery is an area of active research that should eventually provide the means to deliver genes by simple injection. Once this has been accomplished, in vivo delivery will clearly become the method of choice for most human applications.
Finally, there is the issue of whether to deliver genes locally to discrete areas of disease activity or systemically, where the genes and their products become more generally distributed. Local delivery produces less side effects and is suitable for autoimmune diseases, such as Grave’s disease, which primarily affects a discrete anatomical location. Systemic delivery, in contrast, seems better suited to the treatment of disseminated autoimmune diseases like lupus. It is unclear whether local or systemic delivery, or some combination of the two, would be most applicable to RA, which, although primarily affecting joints, has important extraarticular components.

Which genes to use?
To cure an autoimmune disease, it is necessary to eliminate the immune system’s response to the inciting autoantigen. In the absence of a cure, it may be possible to treat the disease very effectively by suppressing those components of the immune response that lead to the disorder. Candidate agents in the latter context include antigen presentation, T lymphocyte activation, and cytokine function. An important distinction between curing and treating diseases, as outlined here, concerns the required period of gene expression. A gene that selectively eliminates autoreactive cells might need to be expressed for only a short period of time. A gene that treats the disease, in contrast, might need to be expressed for the life of the patient.

At our present state of knowledge, the best chance of a permanent effect in autoimmune disease is to eliminate autoreactive cells or to induce selective tolerance to the inciting antigen. Selective elimination of certain sub-sets of lymphocytes can be achieved with antibodies that recognize specific cell surface markers. There is presently much interest in eliminating autoreactive T cells by transferring genes encoding Fas ligand. Preliminary evidence suggests that selective tolerance can be achieved by blocking interactions between co-stimulatory ligand pairs such as CD40/CD40L and B7/CD28. Soluble CTLA-4 has emerged as a particularly promising molecule in this regard. This strategy has the advantage of not necessarily requiring knowledge of the autoantigen.

In many cases, the pathophysiology of autoimmune disease is driven by an imbalance in the activities of Th-1 and Th-2 lymphocytes. Redressing this imbalance offers an alternative approach to therapy. There is of particular interest in the use of interleukin 12 (IL12), a product of Th-1 lymphocytes, to treat diseases such as lupus in which Th-2 activity is thought to be excessive, and in the use of IL10, a product of Th-2 lymphocytes, to treat diseases such as inflammatory bowel disease where Th-1 activity is thought to be excessive. IL10 has the additional advantage of being, like IL4 and IL13, an anti-inflammatory cytokine with the ability to antagonise the biological activities of cytokines such as IL1 and TNFα. These two pro-inflammatory cytokines can also be inhibited with specific antagonists such as soluble receptors and IL1Ra. Table 1 lists the proteins with potential use in autoimmune diseases.

Therapeutic gene products need not be limited to secreted proteins. Intracellular processes in the transduced cells may be targeted with intracellular proteins and species of RNA, such as anti-sense RNA and ribozymes. There is interest in using these approaches to block the actions of certain transcription factors, particularly NF-κB and AP-1. One limitation of targeting intracellular molecules is that ex vivo gene therapy is unlikely to be useful, and very high transduction efficiencies are probably required.

Pre-clinical findings
Data from pre-clinical studies in a variety of different animal models permit guarded optimism about the future of gene therapy in autoimmune diseases. Raz et al have shown that the immune responsiveness of mice can be selectively modulated by the intramuscular injection of naked, plasmid DNA. Injection of DNA encoding IL2 increased immune function, while injection of DNA encoding TGFβ was immunosuppressive. Using this approach, it was possible to alter disease activity in murine lupus13 and experimental colitis in rats. Most attention, however, has been directed toward treatment of rheumatoid arthritis, the most common autoimmune disease. An anti-arthritic effect has been noted after transfer to synovium of genes encoding IL1Ra14−16, IL1sRα, and ‘TNFβR’17; injection of “decoy” oligonucleotides containing NF-κB18 and AP-119 recognition sequences has also proved effective. In certain cases, a pronounced anti-arthritic effect has been noted in other joints on the same animal. This effect is clearly important as it, to some degree, meets the concerns of those who consider local gene therapy to be unsuited to a polyarticular, systemic disease like rheumatoid arthritis. An alternative way to tackle these issues is to transfer genes to cells such as lymphocytes with the potential to home to affected joints. There is preliminary evidence that this approach has merit. Ex vivo retroviral transduction of T lymphocytes with IL 4 cDNA also reduces disease activity in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Potentially anti-arthritic genes have also been transferred to the haematopoietic stem cells of mice. This produces high, lifelong, circulating levels of the gene product. Expression of IL1Ra and ‘TNFβR’ in this way reduces certain responses to endotoxin, suggesting that these products are biologically active and able to inhibit acute inflammatory reactions.

Human trials
The first human gene therapy trial for an autoimmune disease started last year. Nine patients with RA will be treated by ex vivo retroviral delivery of a CDNA encoding human IL1Ra. Because this is the first human use of gene therapy for a disease that is not considered lethal, the

### Table 1 Gene products of potential use in the treatment of autoimmune diseases

<table>
<thead>
<tr>
<th>Product</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soluble CD40, CTLA, Fas L</td>
<td>Inhibit lymphocyte activation, may induce tolerance</td>
</tr>
<tr>
<td>Antibody to CD4, CD5, CD7, CD52, etc Antibody to IL2</td>
<td>Induces apoptosis in lymphocytes and other cells expressing Fas</td>
</tr>
<tr>
<td>Antibody to TCR specifically present on autoreactive T cells</td>
<td>Eliminate various subsets of lymphocytes. Inhibits T cell activation</td>
</tr>
<tr>
<td>IL-12</td>
<td>Eliminates autoreactive T cells</td>
</tr>
<tr>
<td>IL-10, IL-4</td>
<td>Inhibits Th-2 lymphocyte activity</td>
</tr>
<tr>
<td>IL1Ra, sIL1RI, sIL1RII</td>
<td>Inhibits Th-1 lymphocyte activity</td>
</tr>
<tr>
<td>sTNFRI, sTNFRII</td>
<td>Antagonise IL1</td>
</tr>
<tr>
<td>IL4, IL10, IL13</td>
<td>Antagonise TNF</td>
</tr>
<tr>
<td>Antibodies to IL1, IL6, TNF, etc</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Ribozymes, antisense RNA, decoy RNA</td>
<td>Inhibit their cognate cytokine</td>
</tr>
<tr>
<td>Modulate gene expression</td>
<td></td>
</tr>
</tbody>
</table>

Finally, there is the issue of whether to deliver genes locally to discrete areas of disease activity or systemically, where the genes and their products become more generally distributed. Local delivery produces less side effects and is suitable for autoimmune diseases, such as Grave’s disease, which primarily affects a discrete anatomical location. Systemic delivery, in contrast, seems better suited to the treatment of disseminated autoimmune diseases like lupus. It is unclear whether local or systemic delivery, or some combination of the two, would be most applicable to RA, which, although primarily affecting joints, has important extraarticular components.

Which genes to use?
To cure an autoimmune disease, it is necessary to eliminate the immune system’s response to the inciting autoantigen. In the absence of a cure, it may be possible to treat the disease very effectively by suppressing those components of the immune response that lead to the disorder. Candidate agents in the latter context include antigen presentation, T lymphocyte activation, and cytokine function. An important distinction between curing and treating diseases, as outlined here, concerns the required period of gene expression. A gene that selectively eliminates autoreactive cells might need to be expressed for only a short period of time. A gene that treats the disease, in contrast, might need to be expressed for the life of the patient.

At our present state of knowledge, the best chance of a permanent effect in autoimmune disease is to eliminate autoreactive cells or to induce selective tolerance to the inciting antigen. Selective elimination of certain sub-sets of lymphocytes can be achieved with antibodies that recognize specific cell surface markers. There is presently much interest in eliminating autoreactive T cells by transferring genes encoding Fas ligand. Preliminary evidence suggests that selective tolerance can be achieved by blocking interactions between co-stimulatory ligand pairs such as CD40/CD40L and B7/CD28. Soluble CTLA-4 has emerged as a particularly promising molecule in this regard. This strategy has the advantage of not necessarily requiring knowledge of the autoantigen.

In many cases, the pathophysiology of autoimmune disease is driven by an imbalance in the activities of Th-1 and Th-2 lymphocytes. Redressing this imbalance offers an alternative approach to therapy. There is of particular interest in the use of interleukin 12 (IL12), a product of Th-1 lymphocytes, to treat diseases such as lupus in which Th-2 activity is thought to be excessive, and in the use of IL10, a product of Th-2 lymphocytes, to treat diseases such as inflammatory bowel disease where Th-1 activity is thought to be excessive. IL10 has the additional advantage of being, like IL4 and IL13, an anti-inflammatory cytokine with the ability to antagonise the biological activities of cytokines such as IL1 and TNFα. These two pro-inflammatory cytokines can also be inhibited with specific antagonists such as soluble receptors and IL1Ra. Table 1 lists the proteins with potential use in autoimmune diseases.

Therapeutic gene products need not be limited to secreted proteins. Intracellular processes in the transduced cells may be targeted with intracellular proteins and species of RNA, such as anti-sense RNA and ribozymes. There is interest in using these approaches to block the actions of certain transcription factors, particularly NF-κB and AP-1. One limitation of targeting intracellular molecules is that ex vivo gene therapy is unlikely to be useful, and very high transduction efficiencies are probably required.

Pre-clinical findings
Data from pre-clinical studies in a variety of different animal models permit guarded optimism about the future of gene therapy in autoimmune diseases. Raz et al have shown that the immune responsiveness of mice can be selectively modulated by the intramuscular injection of naked, plasmid DNA. Injection of DNA encoding IL2 increased immune function, while injection of DNA encoding TGFβ was immunosuppressive. Using this approach, it was possible to alter disease activity in murine lupus and experimental colitis in rats. Most attention, however, has been directed toward treatment of rheumatoid arthritis, the most common autoimmune disease. An anti-arthritic effect has been noted after transfer to synovium of genes encoding IL1Ra, IL1sRα, and ‘TNFβR’; injection of “decoy” oligonucleotides containing NF-κB and AP-1 recognition sequences has also proved effective. In certain cases, a pronounced anti-arthritic effect has been noted in other joints on the same animal. This effect is clearly important as it, to some degree, meets the concerns of those who consider local gene therapy to be unsuited to a polyarticular, systemic disease like rheumatoid arthritis. An alternative way to tackle these issues is to transfer genes to cells such as lymphocytes with the potential to home to affected joints. There is preliminary evidence that this approach has merit. Ex vivo retroviral transduction of T lymphocytes with IL 4 cDNA also reduces disease activity in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Potentially anti-arthritic genes have also been transferred to the haematopoietic stem cells of mice. This produces high, lifelong, circulating levels of the gene product. Expression of IL1Ra and ‘TNFβR’ in this way reduces certain responses to endotoxin, suggesting that these products are biologically active and able to inhibit acute inflammatory reactions.

Human trials
The first human gene therapy trial for an autoimmune disease started last year. Nine patients with RA will be treated by ex vivo retroviral delivery of a CDNA encoding human IL1Ra. Because this is the first human use of gene therapy for a disease that is not considered lethal, the...
overriding priority has been to establish the safety of gene transfer to diseased joints. Among the safety features of this protocol are: the use of a gene whose product, IL-1Ra, has a highly favourable toxicological profile; the use of ev vivo delivery so that cells may be thoroughly tested before re-implantation; extensive screening for replication competent retrovirus and other adventitious agents; surgical removal of the genetically altered joints as part of joint replacement surgery one week after gene transfer.

Details of the human protocol are given elsewhere. To abbreviate, participants need to be post-menopausal or women with rheumatoid arthritis who have had an ovarectomy whose surgical management requires replacement of the metacarpophalangeal joints 2–5 and at least one other prior arthroplasty. Autologous synovium is recovered at the time of the prior joint surgery. Synovial fibroblasts are grown from it, and half the cultures are transduced with the retrovirus MFG-IRAP. Having confirmed that transduced cultures are secreting sufficient IL1Ra, aliquots of both the transduced and untransduced cells are extensively tested for a variety of adventitious agents and endotoxin. After satisfactory test results, the remaining cells are prepared for injection into the metacarpo-phalangeal joints. In a blinded fashion, two joints receive untransduced, control cells and the other two receive transduced cells secreting IL1Ra. One week later, synovia are harvested and tested for evidence of transgene expression and a local biological response to the transgene product. So far, five patients have been treated in this way. A similar trial was recently started at the University of Düsseldorf.

Conclusions
Gene therapy offers promising new avenues for treating autoimmunity diseases. Very encouraging pre-clinical data have led to the first human trials. This permits optimism about the future development and clinical application of this approach to a wide spectrum of autoimmune conditions. Now that proof of principle has been established, the next goals are to determine the best gene, or combination of genes, to use in each disease, to develop improved gene delivery systems, and to achieve long term, regulated gene expression.

C H EVANS
J D WHALEN
Department of Orthopaedic Surgery
and Molecular Genetics and Biochemistry,
University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA

Correspondence to: Professor C H Evans, Orthopaedic Surgery, University Medical Center, 200 Lothrop Street, room C-313 Presbyterian University Hospital, Pittsburgh, PA 15213, USA.

22 Boggs SS, Patrén KD, Muellier GM, Evans CH, Dougherty LA, Robbins PD. Prolonged systemic expression of human IL-1 receptor antagonist (hIL-1ra) in mice reconstituted with hematopoietic cells transduced with a retrovirus carrying the hIL-1ra cDNA. Gene Ther 1995;2:632–8.